Rights and permissions
About this article
Cite this article
Celecoxib most cost-effective choice in high-risk arthritis patients. Inpharma Wkly. 1480, 4 (2005). https://doi.org/10.2165/00128413-200514800-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200514800-00006